Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Basal Cell Carcinoma (Basal Cell Epithelioma) Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) Overview | 8 | 1 |
| Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics under Development by Companies | 9 | 1 |
| Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Basal Cell Carcinoma (Basal Cell Epithelioma) Products under Development by Companies | 13 | 1 |
| Basal Cell Carcinoma (Basal Cell Epithelioma) Companies Involved in Therapeutics Development | 14 | 13 |
| Biofrontera AG | 14 | 1 |
| Biosceptre (Aust) Pty Ltd | 15 | 1 |
| Cannabis Science, Inc | 16 | 1 |
| Genextra S.p.a. | 17 | 1 |
| Ignyta, Inc. | 18 | 1 |
| Laboratories Ojer Pharma S.L. | 19 | 1 |
| MediGene AG | 20 | 1 |
| Merck &Co., Inc. | 21 | 1 |
| PellePharm, Inc. | 22 | 1 |
| Provectus Biopharmaceuticals, Inc. | 23 | 1 |
| Redx Pharma Plc | 24 | 1 |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 25 | 1 |
| Transgene SA | 26 | 1 |
| Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics Assessment | 27 | 10 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Combination Products | 28 | 1 |
| Assessment by Target | 29 | 2 |
| Assessment by Mechanism of Action | 31 | 2 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Drug Profiles | 37 | 69 |
| aminolevulinic acid hydrochloride Drug Profile | 37 | 4 |
| aminolevulinic acid hydrochloride Drug Profile | 41 | 1 |
| BIL-010t Drug Profile | 42 | 1 |
| BLR-300 Drug Profile | 43 | 1 |
| CS-S/BCC-1 Drug Profile | 44 | 1 |
| CSTATI-1 Drug Profile | 45 | 2 |
| DAC-060 Drug Profile | 47 | 1 |
| imiquimod SR Drug Profile | 48 | 1 |
| Oshadi D + Oshadi R Drug Profile | 49 | 1 |
| patidegib hydrochloride Drug Profile | 50 | 1 |
| pembrolizumab Drug Profile | 51 | 31 |
| PV-10 Drug Profile | 82 | 18 |
| RDX-001 Drug Profile | 100 | 1 |
| sinecatechins Drug Profile | 101 | 1 |
| taladegib Drug Profile | 102 | 2 |
| TG-1042 Drug Profile | 104 | 2 |
| Basal Cell Carcinoma (Basal Cell Epithelioma) Dormant Projects | 106 | 1 |
| Basal Cell Carcinoma (Basal Cell Epithelioma) Discontinued Products | 107 | 1 |
| Basal Cell Carcinoma (Basal Cell Epithelioma) Product Development Milestones | 108 | 3 |
| Featured News &Press Releases | 108 | 1 |
| Jul 28, 2016: Biofrontera Receives Favourable CHMP Assessment for Field-Directed Therapy and Files BCC Application | 108 | 1 |
| Jun 23, 2016: Biofrontera Progresses with Expansion of U.S. Subsidiary with Key Personnel Hires | 108 | 1 |
| Nov 19, 2015: Biofrontera reports final patient visit in phase III trial for basal cell carcinoma | 109 | 1 |
| Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma | 109 | 1 |
| Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi s Sarcoma | 110 | 1 |
| Appendix | 111 | 2 |
| Methodology | 111 | 1 |
| Coverage | 111 | 1 |
| Secondary Research | 111 | 1 |
| Primary Research | 111 | 1 |
| Expert Panel Validation | 111 | 1 |
| Contact Us | 111 | 1 |
| Disclaimer | 112 | 1 |